217 related articles for article (PubMed ID: 26503203)
1. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Renfro LA; Loupakis F; Adams RA; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Falcone A; Tebbutt NC; Punt CJ; Hecht JR; Bokemeyer C; Van Cutsem E; Goldberg RM; Saltz LB; de Gramont A; Sargent DJ; Lenz HJ
J Clin Oncol; 2016 Jan; 34(2):144-50. PubMed ID: 26503203
[TBL] [Abstract][Full Text] [Related]
2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Aparicio T; Ducreux M; Faroux R; Barbier E; Manfredi S; Lecomte T; Etienne PL; Bedenne L; Bennouna J; Phelip JM; François E; Michel P; Legoux JL; Gasmi M; Breysacher G; Rougier P; De Gramont A; Lepage C; Bouché O; Seitz JF;
Eur J Cancer; 2018 Jul; 98():1-9. PubMed ID: 29807237
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
4. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
Lieu CH; Renfro LA; de Gramont A; Meyers JP; Maughan TS; Seymour MT; Saltz L; Goldberg RM; Sargent DJ; Eckhardt SG; Eng C;
J Clin Oncol; 2014 Sep; 32(27):2975-84. PubMed ID: 25002720
[TBL] [Abstract][Full Text] [Related]
5. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
[TBL] [Abstract][Full Text] [Related]
6. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
7. A paradox between preoperative overweight/obesity and change in weight during postoperative chemotherapy and its relationship to survival in stage Ⅱ and Ⅲ colorectal cancer patients.
Hu C; Zhang Q; Jin X; Zhang L; Zhang Y; Zhu Q; Tang M; Lyv G; Shi H
Clin Nutr; 2021 Apr; 40(4):2410-2419. PubMed ID: 33183882
[TBL] [Abstract][Full Text] [Related]
8. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Dell'Aquila E; Rossini D; Galletti A; Stellato M; Boccaccino A; Conca V; Germani MM; Bergamo F; Daniel F; Spagnoletti A; Provenzano L; Tomasello G; Zaniboni A; Buonadonna A; Fanchini L; Cupini S; Carlomagno C; Caponnetto S; Rapisardi S; Santini D
Clin Colorectal Cancer; 2022 Sep; 21(3):220-228. PubMed ID: 35304089
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
11. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
12. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
15. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Dec; 18(4):e385-e393. PubMed ID: 31378656
[TBL] [Abstract][Full Text] [Related]
16. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q; de Gramont A; Grothey A; Zalcberg J; Chibaudel B; Schmoll HJ; Seymour MT; Adams R; Saltz L; Goldberg RM; Punt CJ; Douillard JY; Hoff PM; Hecht JR; Hurwitz H; Díaz-Rubio E; Porschen R; Tebbutt NC; Fuchs C; Souglakos J; Falcone A; Tournigand C; Kabbinavar FF; Heinemann V; Van Cutsem E; Bokemeyer C; Buyse M; Sargent DJ
J Clin Oncol; 2015 Jan; 33(1):22-8. PubMed ID: 25385741
[TBL] [Abstract][Full Text] [Related]
17. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
18. Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer.
van der Werf A; van Bokhorst QNE; de van der Schueren MAE; Verheul HMW; Langius JAE
Nutr Cancer; 2018; 70(8):1322-1329. PubMed ID: 30235002
[TBL] [Abstract][Full Text] [Related]
19. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
[TBL] [Abstract][Full Text] [Related]
20. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.
Franko J; Yin J; Adams RA; Zalcberg J; Fiskum J; Van Cutsem E; Goldberg RM; Hurwitz H; Bokemeyer C; Kabbinavar F; Curtis A; Meyers J; Chibaudel B; Yoshino T; de Gramont A; Shi Q;
Eur J Cancer; 2022 Oct; 174():142-152. PubMed ID: 35994794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]